← Leaderboards
Stuart B Goodman
Stanford University
$11,095,064
Attributed
$15,190,131
Total exposure
10
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,190,131 · 10
By mechanism
R01$12,716,117 · 6
U01$1,601,083 · 1
R34$470,226 · 1
R21$372,705 · 1
U13$30,000 · 1
Top collaborators
- Yunzhi Yang5 shared
- Bruce A Bunnell4 shared
- Lynne C. Jones4 shared
- Hang Lin4 shared
- Michael Mont4 shared
Most similar at Stanford University
Same institution · by research overlap
- Sarah C Heilshorn$11,238,436
- Joseph C Wu$80,370,369
- Hongjie Dai$7,329,221
- Michael Lim$6,380,630
- Scott Dexter Boyd$18,651,021
Others in their field
Top investigators on “Bone”
- David Heimbrook · Leidos Biomedical Research, Inc.$240,577,094
- Charles A Coltman · Southwest Oncology Group$141,983,231
- Mary M Horowitz · Medical College Of Wisconsin$136,789,389
- Gregory D Peterson · University Of Tennessee Knoxville$84,527,696
- Richard A Gibbs · Baylor College Of Medicine$64,141,825
- Jeffrey Krischer · University Of South Florida$61,545,982
Research focus
BoneCellsOperative Surgical ProceduresGrantMacrophageImplantOsseointegrationInflammatoryParticleIn VivoArthritisSignal TransductionInflammationChronicBone LossAreaCytokineIn VitroOsteolysisReplacement ArthroplastyReporterChemokineInfusion ProceduresPhenotype
Grant awards (40)
Defining the unique capacity of the miniature joint model for investigating the role of adipose tissue and its impacts on osteoarthritis$653,310
R01 · FY2025 · AR
Repurposing FDA-approved drugs for the treatment of osteoarthritis using high-throughput screening in microphysiological models$514,092
R01 · FY2025 · AR
Autologous Bone Marrow Aspirate Concentrate for the Treatment of Osteonecrosis of the Femoral Head$822,027
U01 · FY2024 · AR
Defining the unique capacity of the miniature joint model for investigating the role of adipose tissue and its impacts on osteoarthritis$711,760
R01 · FY2024 · AR
Repurposing FDA-approved drugs for the treatment of osteoarthritis using high-throughput screening in microphysiological models$571,650
R01 · FY2024 · AR
Autologous Bone Marrow Aspirate Concentrate for the Treatment of Osteonecrosis of the Femoral Head$779,056
U01 · FY2023 · AR
Tissue Engineering Approaches for Improved Treatment of Early Stage Osteonecrosis of the Hip$426,524
R01 · FY2022 · AR
Tissue Engineering Approaches for Improved Treatment of Early Stage Osteonecrosis of the Hip$417,842
R01 · FY2021 · AR
Customized MSCs to Enhance Healing of Bone Defects$346,868
R01 · FY2021 · AR · contact PI
Enhanced Bone Healing Around Implants by Transplanted NF-kB Driven Immunomodulating MSCs$335,153
R01 · FY2021 · AR · contact PI
Tissue Engineering Approaches for Improved Treatment of Early Stage Osteonecrosis of the Hip$427,718
R01 · FY2020 · AR
Customized MSCs to Enhance Healing of Bone Defects$347,266
R01 · FY2020 · AR · contact PI
Enhanced Bone Healing Around Implants by Transplanted NF-kB Driven Immunomodulating MSCs$345,520
R01 · FY2020 · AR · contact PI
Cell-Based Autogenous Grafting for the Treatment of Femoral Head Osteonecrosis$218,378
R34 · FY2020 · AR
Tissue Engineering Approaches for Improved Treatment of Early Stage Osteonecrosis of the Hip$435,176
R01 · FY2019 · AR
Customized MSCs to Enhance Healing of Bone Defects$346,470
R01 · FY2019 · AR · contact PI
Enhanced Bone Healing Around Implants by Transplanted NF-kB Driven Immunomodulating MSCs$345,520
R01 · FY2019 · AR · contact PI
Cell-Based Autogenous Grafting for the Treatment of Femoral Head Osteonecrosis$251,848
R34 · FY2019 · AR
Tissue Engineering Approaches for Improved Treatment of Early Stage Osteonecrosis of the Hip$453,379
R01 · FY2018 · AR
Customized MSCs to Enhance Healing of Bone Defects$345,758
R01 · FY2018 · AR · contact PI
Enhanced Bone Healing Around Implants by Transplanted NF-kB Driven Immunomodulating MSCs$345,520
R01 · FY2018 · AR · contact PI
Enhanced Bone Healing Around Implants by Transplanted NF-kB Driven Immunomodulating MSCs$345,520
R01 · FY2017 · AR · contact PI
Biological Strategies to Mitigate the Adverse Effects of Polymeric Wear Particles$353,822
R01 · FY2016 · AR · contact PI
Wear Particle Disease and NF-kappa B Signaling$353,307
R01 · FY2016 · AR · contact PI
Biological Strategies to Mitigate the Adverse Effects of Polymeric Wear Particles$354,135
R01 · FY2015 · AR · contact PI
Wear Particle Disease and NF-kappa B Signaling$353,304
R01 · FY2015 · AR · contact PI
Biological Strategies to Mitigate the Adverse Effects of Polymeric Wear Particles$346,504
R01 · FY2014 · AR · contact PI
Wear Particle Disease and NF-kappa B Signaling$346,288
R01 · FY2014 · AR · contact PI
Biological Strategies to Mitigate the Adverse Effects of Polymeric Wear Particles$176,781
R01 · FY2014 · AR · contact PI
Biological Strategies to Mitigate the Adverse Effects of Polymeric Wear Particles$335,938
R01 · FY2013 · AR · contact PI
Wear Particle Disease and NF-kappa B Signaling$335,635
R01 · FY2013 · AR · contact PI
Wear Particle Disease and NF-kappa B Signaling$353,361
R01 · FY2012 · AR · contact PI
Biological Strategies to Mitigate the Adverse Effects of Polymeric Wear Particles$353,250
R01 · FY2012 · AR · contact PI
Chemokine Directed Cell Trafficking during Continuous Infusion of Wear Particles$329,775
R01 · FY2010 · AR · contact PI
Chemokine Directed Cell Trafficking during Continuous Infusion of Wear Particles$335,998
R01 · FY2009 · AR · contact PI
Chemokine Directed Cell Trafficking during Continuous Infusion of Wear Particles$333,091
R01 · FY2008 · AR · contact PI
Chemokine Directed Cell Trafficking during Continuous Infusion of Wear Particles$339,882
R01 · FY2007 · AR · contact PI
Osteolysis and Implant Wear: Biological, Biomedical Engineering, and Surgical Pri$30,000
U13 · FY2007 · AR · contact PI
Infusion of Particles at Implant interfeces$201,081
R21 · FY2006 · AR · contact PI
Infusion of Particles at Implant interfeces$171,624
R21 · FY2005 · AR